Strand AI
ActiveAI-nativeMultimodal foundation models to predict uncollected patient biology
What it does
Strand AI develops foundation models to generate missing bio-data about patients. With this imputed data, pharmaceutical companies can select better patients for their drug trials and shave months from their drug launch timelines. We’ve already trained a multimodal foundation model that integrates spatial biology modalities, beating SOTA at a fraction of the cost.
Its site says now · captured 2026-08-23
Strand AI — Multimodal Patient Data for Life Sciences & Drug Discovery
Strand AI generates missing multimodal patient data — gene expression, proteomics, spatial transcriptomics — from routinely collected samples. For life sciences teams running clinical trials and biomarker discovery.
Next to it in Healthcare and bio · AI-generated patient biodata for drug trials
- Ditto BiosciencesY Combinator W26
Evolutionary intelligence for autoimmune disease
- Anto BiosciencesY Combinator F25
A Foundation Model for Microbial Communities.
- Diffuse BioY Combinator W23
Generative AI for protein design
- 10x ScienceY Combinator W26
The AI-native platform for next-generation protein characterization.
- Grannus TherapeuticsPlug and Play PnP 2025
Grannus Therapeutics is a preclinical biotech startup, focused on developing novel first-in-class Hsp90𝛽-selective inhibitors for the treatment of multiple solid tumors.
- Intero BiosystemsPlug and Play PnP 2025
Miniature Human Organs for Preclinical Drug Development.
- elegslabPlug and Play PnP 2026
elegslab accelerates drug discovery with AI-automated C. elegans platforms—a next-generation NAMs solution.
- PaulingPlug and Play PnP 2025
Next-generation molecular simulation platform for drug discovery.